SCHEMBL5869831

SCHEMBL5869831

CC(C)C[C@H](N[C@@H](CC(=O)Nc1nc2ccccc2s1)C(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 7/20 0.62
NCS1 P62166 1/20 0.62
ALDH1A1 P00352 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
POLB P06746 1/20 0.55
TSHR P16473 1/20 0.54
MAPK1 P28482 3/20 0.52
KDM4E B2RXH2 1/20 0.52
HTT P42858 1/20 0.52
ADORA1 P30542 1/20 0.51
DYRK1A Q13627 1/20 0.51
MEN1 O00255 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 2/20 0.51
ACP1 P24666 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869854 1.00 CSNK1D (0.62) CSNK1DNCS1ALDH1A1SMN1; SMN2NPC1
SCHEMBL5869819 1.00 CSNK1D (0.62) CSNK1DNCS1ALDH1A1SMN1; SMN2NPC1
SCHEMBL5869719 0.86 RAB9A (0.59) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5869705 0.86 RAB9A (0.59) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5869749 0.86 RAB9A (0.59) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5870526 0.85 PDPK1 (0.55) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5681071 0.85 RAB9A (0.55) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5681078 0.85 RAB9A (0.55) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5870537 0.85 PDPK1 (0.55) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5870315 0.85 PDPK1 (0.55) CSNK1DALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045532-B2 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-16 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 CSNK1D 722/4885NCS1 3472/4885ALDH1A1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.